Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparative Study of TECNIS Symfony Plus IOL and a Trifocal IOL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04156737
Recruitment Status : Not yet recruiting
First Posted : November 7, 2019
Last Update Posted : November 7, 2019
Sponsor:
Information provided by (Responsible Party):
Johnson & Johnson Surgical Vision, Inc.

Brief Summary:
This is a multicenter, prospective, randomized, subject- and evaluator-masked, bilateral-implant study conducted at up to 15 sites worldwide. A total of up to 280 subjects will be randomized in a 1:1 ratio for implantation with either the TECNIS Symfony plus IOL Model ZHR00V or the Trifocal IOL. This will ensure that data from at least 100 subjects in the TECNIS Symfony plus lens group and at least 100 subjects in the Trifocal lens group will be available for analysis at the 6-month follow-up timepoint. All subjects will be followed for up to 6 months postoperative.

Condition or disease Intervention/treatment Phase
Cataract Refractive Error Device: TECNIS Symfony plus IOL Model ZHR00V Device: Trifocal Intraocular lens Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Care Provider)
Masking Description: Unmasked study personnel at the site will be trained to the randomization process through the EDC system and will randomize subjects. The surgeon and the operative staff will know which lens type is implanted. There may also be site coordinators and other site study staff, such as those performing slit-lamp exams, who will be unmasked. Unmasked study site staff will be instructed not to disclose the lens type the subject received or to talk about the lens to any masked evaluators or to the study subjects. The subjects and the study technicians performing the postoperative vision tests are to be masked through study completion. To maintain subject masking, a temporary IOL implant identification card will be issued to the subject at the time of surgery. Following completion of the final study exam, each subject will be given the permanent IOL implant identification card.
Primary Purpose: Treatment
Official Title: A Comparative Clinical Evaluation of a New TECNIS® Presbyopia-correcting Intraocular Lens Against a Trifocal Intraocular Lens
Estimated Study Start Date : November 15, 2019
Estimated Primary Completion Date : January 31, 2021
Estimated Study Completion Date : April 30, 2021

Arm Intervention/treatment
Experimental: Investigational Lens
TECNIS Symfony plus IOL Model ZHR00V
Device: TECNIS Symfony plus IOL Model ZHR00V
IOL replaces the natural lens removed during cataract surgery

Active Comparator: Control Lens
Trifocal Intraocular Lens
Device: Trifocal Intraocular lens
IOL replaces the natural lens removed during cataract surgery




Primary Outcome Measures :
  1. Binocular distance-corrected VA of 20/25 [ Time Frame: 3 months ]
    Percent of subjects who achieve binocular distance-corrected VA of 20/25 (6.7.5) Snellen or better at far, intermediate, and near (40 cm)

  2. Binocular uncorrected VA of 20/32 [ Time Frame: 3 months ]
    Percent of subjects who achieve binocular uncorrected VA of 20/32 or better at far and near (40 cm)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

(all criteria apply to both eyes):

  • Age 22 and older
  • Bilateral cataracts or clear crystalline lenses for which posterior chamber IOL implantation has been planned
  • Potential postoperative best corrected distance visual acuity (BCDVA) of 0.66 decimal (20/30 or 6/9 Snellen) or better
  • Predicted postoperative corneal astigmatism less than 1.0 D, including posterior corneal astigmatism (PCA)
  • Clear intraocular media other than cataract in each eye
  • Availability, willingness and sufficient cognitive awareness to comply with examination procedures
  • Ability to understand, read, and write English or the local language in which the informed consent and questionnaires are provided
  • Written informed consent for participation in the study and data protection.

Exclusion Criteria:

  • (including device labeling, all criteria apply to both eyes):

    • Require an intraocular lens power outside the available range of +14.0 to +26.0 D
    • Irregular corneal astigmatism (as evaluated by topography)
    • Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery, including prophylactic peripheral iridotomies and peripheral laser retinal repairs
    • Corneal abnormalities such as stromal, epithelial or endothelial dystrophies (e.g., any observed guttata) that are predicted to cause visual acuity loss to a level worse than 0.66 decimal (20/30 or 6/9 Snellen) during the study
    • Inability to achieve keratometric stability for contact lens wearers
    • Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject
    • Pupil abnormalities that may affect visual outcomes or increase risk to the subject
    • Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity loss to a level worse than 0.66 decimal (20/30 or 6/9 Snellen) during the study
    • Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects
    • Use of systemic or ocular medications that, in the opinion of the investigator, may affect vision
    • Prior, current, or anticipated use during the 6-month study of tamsulosin or silodosin that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery)
    • Poorly-controlled diabetes or hypertension that, in the opinion of the investigator, may mpact visual outcome or increase the risk to the subject
    • Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.). Note: controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable.
    • Known ocular disease or pathology that, in the opinion of the investigator,

      • may affect visual acuity (e.g., ocular surface conditions)
      • may require surgical intervention during the study (macular degeneration, cystoid macular edema, diabetic retinopathy, uncontrolled glaucoma, etc.)
      • may be expected to require retinal laser treatment or other surgical intervention during the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)
    • Pregnancy, planned pregnancy, presently lactating, or another condition associated with hormonal fluctuation that could lead to refractive changes
    • Concurrent participation or participation within 60 days prior to the preoperative visit in any other clinical trial
    • Desire for monovision correction

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04156737


Contacts
Layout table for location contacts
Contact: Anne Buteyn +1 949 505-2029 abuteyn@its.jnj.com

Locations
Layout table for location information
New Zealand
Auckland Eye Institute Not yet recruiting
Remuera, Auckland, New Zealand, 1050
Philippines
Asian Eye Institute Not yet recruiting
Makati, Philippines, 1200
Singapore
Seri/Snec Not yet recruiting
Singapore, Singapore, 168753
Tan Tock Seng Hospital Not yet recruiting
Singapore, Singapore, 308433
Sponsors and Collaborators
Johnson & Johnson Surgical Vision, Inc.
Investigators
Layout table for investigator information
Study Director: Devi Priya Janakiraman, OD, FAAO Johnson & Johnson Surgical Vision

Layout table for additonal information
Responsible Party: Johnson & Johnson Surgical Vision, Inc.
ClinicalTrials.gov Identifier: NCT04156737     History of Changes
Other Study ID Numbers: SUR-IOL-652-3002
First Posted: November 7, 2019    Key Record Dates
Last Update Posted: November 7, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Johnson & Johnson Medical Devices Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA project site at http://yoda.yale.edu
URL: http://yoda.yale.edu/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cataract
Refractive Errors
Lens Diseases
Eye Diseases